Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer



Status:Archived
Conditions:Ovarian Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:October 2008

Use our guide to learn which trials are right for you!

A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer


This is a multicenter, open-label, two-arm, 2-stage, Phase 2 study of NKTR-102 in patients
with metastatic or locally advanced platinum-resistant ovarian cancer.

Patients will be randomized 1:1 into one of two treatment arms. NKTR-102 will be
administered at a dose level of 145 mg/m2 in both arms. In Arm A, NKTR-102 will be given on
a q14d schedule. In Arm B, NKTR-102 will be given on a q21d schedule. Approximately 70
patients may be evaluated in this study with approximately 35 patients in each treatment
arm.



We found this trial at
5
sites
1309 North Flagler Drive
West Palm Beach, Florida 33401
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Los Angeles, California 90089
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
230 25th Ave N
Nashville, Tennessee 37203
(615) 329-7274
Sarah Cannon Cancer Center People who live with cancer
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Newport Beach, California 92663
?
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Winston-Salem, North Carolina 27103
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials